Floatz logo

Nab-Rapamycin

PEComa

Sarcoma Oncology Research Center, LLCPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the PEComa cohort.

Asset / SponsorPhaseRating
Nivolumab
Sarcoma Oncology Research Center, LLC
Phase 2B
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
DACTOLISIB
Novartis Pharmaceuticals
Phase 2CCC
Ivocizumab
Fudan University
Phase 2NR

Same molecule, other indications

Nab-Rapamycin is also rated in:

epithelioid sarcomaDormant
CCC
Indicative ·
52 / 100
View asset →
desmoid tumorDormant
CCC
Indicative ·
52 / 100
View asset →
chordomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →